Zobrazeno 1 - 10
of 28
pro vyhledávání: '"B. Sh. Kamolov"'
Autor:
P. G. Gabay, B. Sh. Kamolov
Publikováno v:
Опухоли головы и шеи, Vol 13, Iss 1, Pp 75-80 (2023)
Introduction. Oncological and palliative patients undergo treatment causing adverse events including mental and cognitive disorders leading to their inability to express their wishes in the legal sense. This affects the possibility of preparation of
Externí odkaz:
https://doaj.org/article/1c98689251244b2f915654fa2b724d9a
Autor:
F. A. Kossov, B. P. Olimov, G. I. Akhverdieva, B. Sh. Kamolov, I. I. Abdullin, V. O. Panov, E. V. Tarachkova, I. E. Tyurin, Yu. V. Buydenok
Publikováno v:
Вестник рентгенологии и радиологии, Vol 98, Iss 6, Pp 327-336 (2017)
This literature review provides information on the main radiation diagnostic methods and approaches for prostate cancer, which are used in current medical practice both by ultrasound (routine transrectal ultrasound (TRUS), sonoelastography, etc.) and
Externí odkaz:
https://doaj.org/article/984f148aa7ff4ccb892f980cc4c03f8e
Publikováno v:
Onkourologiâ, Vol 17, Iss 2, Pp 83-92 (2021)
Background. Despite the recent amendments to the guidelines for the treatment of metastatic hormone-sensitive prostate cancer (PCa) implying standard use of luteinizing hormone-releasing hormone (LHRH) agonists in combination with chemotherapy or and
Publikováno v:
Onkourologiâ, Vol 2, Iss 3, Pp 30-33 (2020)
Autor:
V. B. Matveev, A. A. Kirichek, V. M. Safronova, N. V. Kokosadze, O. A. Khalmurzaev, B. Sh. Kamolov, L. N. Liubchenko
Publikováno v:
Onkourologiâ, Vol 15, Iss 1, Pp 57-65 (2019)
Background. New potential biomarker for patients with metastatic hormone-naive prostate cancer (PCa) might be detection of programmed death ligand 1 (PD-L1) expression in tumor which is associated with worsened results of treatment and decreased surv
Autor:
N. V. Apanovich, V. I. Loginov, P. V. Apanovich, D. A. Sergeev, T. P. Kazubskaya, B. Sh. Kamolov, E. A. Braga, V. B. Matveev, A. V. Karpukhin
Publikováno v:
Onkourologiâ, Vol 14, Iss 4, Pp 16-21 (2019)
Background . Clear cell renal cell carcinoma is the most frequent and most aggressive kidney cancer. Approximately 30 % at the initial diagnosis reveal distant metastases. This is due to the fact that kidney cancer in the early stages is asymptomatic
Autor:
B. Sh. Kamolov, F.A. Kossov Kossov, I.I. Abdullin Abdullin, Yu.V. Buidenok Buidenok, V.O. Panov Panov, I.L. Gubskii Gubskii, V.B. Matveev Matveev, V.A. Chernyaev Chernyaev, V.V. Kapustin Kapustin, N.A. Grigor’ev Grigor’ev
Publikováno v:
Urologiia. :106-112
AIM The study aimed to analyze the diagnostic performance of preoperative multiparametric magnetic resonance imaging (mp-MRI) in the staging of prostate cancer (PCa) versus postoperative histological examination and determine the most sensitive pulse
Publikováno v:
Onkourologiâ, Vol 14, Iss 3, Pp 143-148 (2018)
The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the
Publikováno v:
Onkourologiâ, Vol 14, Iss 1, Pp 166-172 (2018)
On January 1, 2018, an updated 8 th edition of the international TNM Classification of Malignant Tumors comes into effect. The classification was developed by 2 leading organizations: the American Joint Committee on Cancer (AJCC) and the Union for In
Publikováno v:
Onkourologiâ, Vol 13, Iss 4, Pp 133-140 (2018)
The European Society for Medical Oncology (ESMO) Congress in partnership with the European Association for Cancer Research took place between September 8th and 12th of 2017 in Madrid. In 42 years of its existence, the forum has grown from a regional